首页|帕博利珠单抗治疗黑色素瘤的临床研究进展

帕博利珠单抗治疗黑色素瘤的临床研究进展

扫码查看
黑色素瘤是一种进展快、恶性程度较高的肿瘤,治疗选择局限且预后效果较差.随着免疫治疗和靶向治疗的兴起,黑色素瘤患者的治疗打开了新的篇章.免疫治疗药物帕博利珠单抗是一种人源化免疫球蛋白G4单克隆抗体,能够阻断肿瘤细胞免疫逃逸而达到抗肿瘤作用,单药治疗和联合治疗均显示出应用潜力.本文对帕博利珠单抗的药动学特点、临床研究进展以及不良反应等方面进行综述,以期为黑色素瘤的治疗提供新视角.
Clinical Research Updates of Pembrolizumab in the Treatment of Melanoma
Melanoma is a rapidly progressing,highly malignancy with limited treatment options and poor prognosis.With the introduction of immunotherapy and targeted therapy,the landscape treatment for melanoma are evolved significantly.Immunotherapy drugs pembrolizumab is a humanized immunoglobulin G4 monoclonal antibody,which can block the immune escape of tumor cells and achieve anti-tumor effect.It has shown potential in monotherapy and combination therapy.This article reviews the pharmacokinetic characteristics,clinical research updates and adverse reactions of pembrolizumab in order to provide a new perspective for the treatment of melanoma.

melanomapembrolizumabpharmacokineticsclinical research updatesadverse reactions

林莉莉、杨明东

展开 >

浙江大学医学院附属第二医院药学部,杭州310009

黑色素瘤 帕博利珠单抗 药动学 临床研究进展 不良反应

2024

中国合理用药探索
中国执业药师协会

中国合理用药探索

影响因子:0.62
ISSN:2096-3327
年,卷(期):2024.21(11)